PT - JOURNAL ARTICLE AU - Amar Nath Chatterjee AU - Fahad Al Basir TI - A Model for SARS-CoV-2 Infection with Treatment AID - 10.1101/2020.04.24.20077958 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.24.20077958 4099 - http://medrxiv.org/content/early/2020/09/02/2020.04.24.20077958.short 4100 - http://medrxiv.org/content/early/2020/09/02/2020.04.24.20077958.full AB - The current emergence of coronavirus (SARS-CoV-2) puts the world in threat. The structural research on the receptor recognition by SARS-CoV-2 has identified the key interactions between SARS-CoV-2 spike protein and its host (epithelial cell) receptor, also known as angiotensin-converting enzyme 2 (ACE2). It controls both the crossspecies and human-to-human transmissions of SARS-CoV-2. In view of this, we propose and analyze a mathematical model for investigating the effect of CTL responses over the viral mutation to control the viral infection when a postinfection immunostimulant drug (pidotimod) is administered at regular intervals. Dynamics of the system with and without impulses have been analyzed using the basic reproduction number. This study shows that the proper dosing interval and drug dose both are important to eradicate the viral infection.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.hindawi.com/journals/cmmm/2020/1352982/ Funding StatementThere is no funding for this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:LaterAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe methods and results data used to support the findings of this study are included in the article.